Cite
HARVARD Citation
Rizzello, I. et al. (2021). Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. Leukemia & lymphoma. 62 (8), pp. 1897-1906. [Online].